Researchers found that metformin, a diabetes medication, may reduce the risk of age-related macular degeneration (AMD). Their ...

Age-related macular degeneration (AMD ... some researchers have turned their attention to metformin—a drug better known for treating type 2 diabetes—because of promising data on its overall ...

SOL-1 is now expected to be enrolled and fully randomized by year-end 2024Topline clinical data from SOL-1 are now expected in Q4 2025BEDFORD, ...

Ocugen (OCGN) reported that the FDA has lifted the clinical hold on the investigational new drug application for the Phase 1 clinical ...

Clearside Biomedical’s Phase IIb ODYSSEY study of its drug-device combination CLS-AX (axitinib injectable suspension) has ...

Vabysmo (faricimab-svoa) is a brand-name injection prescribed for certain eye conditions, including wet age-related macular degeneration. The cost of the drug with and without insurance can depend ...

The global AMD drugs market is set to grow from USD 10.46 billion in 2024 to USD 17.37 billion by 2029, reflecting a robust ...

Early results of a real-world study of faricimab demonstrated sustainable improvements in visual acuity and retinal anatomic ...

The quest to find a cure for the UK’s biggest cause of sight loss will be brought sharply into focus at a support group for ...